Efficacy News and Research

RSS
Merck announces new data from ongoing C-WORTHY Study in HIV/HCV co-infected patients

Merck announces new data from ongoing C-WORTHY Study in HIV/HCV co-infected patients

Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

Kamada initiates Phase 2/3 clinical trial of Glassia to treat pediatric patients with T1D

Kamada initiates Phase 2/3 clinical trial of Glassia to treat pediatric patients with T1D

GLNT receives allowance of patent for Parkinson's disease monitoring technology

GLNT receives allowance of patent for Parkinson's disease monitoring technology

Study highlights efficacy of TPF 50 to prevent skin sun damage and non-melanoma skin cancer

Study highlights efficacy of TPF 50 to prevent skin sun damage and non-melanoma skin cancer

Novel HIV prevention products for women demonstrate safety in clinical studies

Novel HIV prevention products for women demonstrate safety in clinical studies

Merck reports results from Phase 2b study of investigational house dust mite sublingual immunotherapy tablet

Merck reports results from Phase 2b study of investigational house dust mite sublingual immunotherapy tablet

Georgia Regents Medical Center explores new treatment for Parkinson's disease-related constipation

Georgia Regents Medical Center explores new treatment for Parkinson's disease-related constipation

Nerve cells from horse stem cells may pave way for cell therapies, say researchers

Nerve cells from horse stem cells may pave way for cell therapies, say researchers

AAA gets orphan drug designation status for radiopharmaceutical, Gallium-68 DOTATATE

AAA gets orphan drug designation status for radiopharmaceutical, Gallium-68 DOTATATE

Omeros submits investigational new drug to initiate OMS721 Phase 2 clinical program

Omeros submits investigational new drug to initiate OMS721 Phase 2 clinical program

GTx provides clinical updates, reports financial results for fourth quarter and full year 2013

GTx provides clinical updates, reports financial results for fourth quarter and full year 2013

Procellera technology enhances cell migration in in-vitro laboratory testing

Procellera technology enhances cell migration in in-vitro laboratory testing

A-PARADDISE consortium obtains funds to develop innovative therapies for neglected parasitic diseases

A-PARADDISE consortium obtains funds to develop innovative therapies for neglected parasitic diseases

New AskRx version 1.0 enables patients to ask health and medication questions

New AskRx version 1.0 enables patients to ask health and medication questions

Oramed to present detailed results from ORMD-0801 Phase 2a trial at 2014 GTC Diabetes Summit

Oramed to present detailed results from ORMD-0801 Phase 2a trial at 2014 GTC Diabetes Summit

Medical student receives award for finding out drugs to treat peripheral vascular disease

Medical student receives award for finding out drugs to treat peripheral vascular disease

LFB SA initiates Phase 3 program for human Factor VIIa in patients with congenital hemophilia

LFB SA initiates Phase 3 program for human Factor VIIa in patients with congenital hemophilia

Researchers identify drug using yeast model that reduces levels of toxic protein in brains of AD patients

Researchers identify drug using yeast model that reduces levels of toxic protein in brains of AD patients

Noninvasive imaging with MRI of carotid artery plaque accurately predicts future cardiovascular events

Noninvasive imaging with MRI of carotid artery plaque accurately predicts future cardiovascular events

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.